UK population based study to predict impact of HPV vaccination

详细信息    查看全文

• 作者：Sam Hibbitts ; Am ; a Tristram ; Helen Beer ; Jane McRea ; Bryan Rose ; Anne Hauke ; Dave Nuttall ; Nick Dallimore ; Robert G. Newcombe ; Alison Fi ; er
• 关键词：Human papillomavirus (HPV) ; Cervical screening ; HPV vaccination ; Cervarix and Gardasil
• 刊名：Journal of Clinical Virology
• 出版年：February, 2014
• 年：2014
• 卷：59
• 期：2
• 页码：109-114
• 全文大小：600 K

文摘

Background

In 2008 a human papillomavirus (HPV) vaccination programme for cervical cancer prevention was implemented in the UK. Surveillance of vaccine uptake, impact on prevalence of HPV infection and cervical cancer incidence were identified as key measures to evaluate the intervention.

Objective

To determine baseline HPV prevalence in unvaccinated women and predict impact of HPV vaccination on high-grade cervical disease (CIN2+).

Study design

A pseudo-anonymous prospective cohort was sampled on entry to the routine cervical screening programme between March 2009 and November 2010. In total, 13,306 eligible females were identified and high-risk (hrHPV) type specific status determined. Potential impact of prophylactic vaccination on CIN2+ was calculated by applying HPV vaccine clinical trial data to the baseline HPV type-specific data.

Results

Of 13,306 samples tested, 3545 (26.6%) were confirmed positive for at least one hrHPV type and 1325 (10%) were positive for low risk HPV. HPV16 was the predominant type detected in cases positive with either single or multiple hrHPV infection(s) (5.2% and 4.7%, respectively). Based on hrHPV type-specific data, Gardasil would have prevented 33.2% HPV16/18 unrelated CIN2+ compared to 47.1% for Cervarix. This difference was not statistically significant.

Conclusion

Prior to the introduction of the HPV vaccine, approximately one-quarter of young women were positive for hrHPV and one-tenth positive for HPV16. Post-vaccination, we anticipate a substantial absolute risk reduction in high-grade cervical disease associated with both targeted and non-targeted hrHPV types. There is no significant difference between the two commercially available vaccines in terms of clinical impact.